Limits...
Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol.

Anholm C, Kumarathurai P, Klit MS, Kristiansen OP, Nielsen OW, Ladelund S, Madsbad S, Sajadieh A, Haugaard SB - BMJ Open (2014)

Bottom Line: The incretin hormone, glucagon-like peptide-1 (GLP-1) improves β-cell function, insulin sensitivity and causes weight loss and has been suggested to have beneficial effects on cardiac function.The GLP-1 receptor agonist (GLP-1RA), liraglutide, is currently used for treatment of T2DM but its potential effect on cardiac function has not been investigated in detail.This study is approved by the Danish Medicines Agency, the Danish Dataprotection Agency and the Regional Committee on Biomedical Research Ethics of the Capital Region of Denmark.

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiology, Copenhagen University Hospital, Bispebjerg, Denmark Department of Internal Medicine, Copenhagen University Hospital, Amager, Denmark.

No MeSH data available.


Related in: MedlinePlus

AddHope2 study design.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4401817&req=5

BMJOPEN2014005942F1: AddHope2 study design.

Mentions: A double blind, randomised, placebo-controlled, crossover, investigator-initiated, human, 12 plus 12 weeks intervention study with a 2-week wash-out period (protocol V.8, February 2013) (figure 1). Inclusion and exclusion criteria are presented in boxes 3 and 4.Box 3Inclusion criteria


Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol.

Anholm C, Kumarathurai P, Klit MS, Kristiansen OP, Nielsen OW, Ladelund S, Madsbad S, Sajadieh A, Haugaard SB - BMJ Open (2014)

AddHope2 study design.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4401817&req=5

BMJOPEN2014005942F1: AddHope2 study design.
Mentions: A double blind, randomised, placebo-controlled, crossover, investigator-initiated, human, 12 plus 12 weeks intervention study with a 2-week wash-out period (protocol V.8, February 2013) (figure 1). Inclusion and exclusion criteria are presented in boxes 3 and 4.Box 3Inclusion criteria

Bottom Line: The incretin hormone, glucagon-like peptide-1 (GLP-1) improves β-cell function, insulin sensitivity and causes weight loss and has been suggested to have beneficial effects on cardiac function.The GLP-1 receptor agonist (GLP-1RA), liraglutide, is currently used for treatment of T2DM but its potential effect on cardiac function has not been investigated in detail.This study is approved by the Danish Medicines Agency, the Danish Dataprotection Agency and the Regional Committee on Biomedical Research Ethics of the Capital Region of Denmark.

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiology, Copenhagen University Hospital, Bispebjerg, Denmark Department of Internal Medicine, Copenhagen University Hospital, Amager, Denmark.

No MeSH data available.


Related in: MedlinePlus